S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Options Trading Plan–Perfect For Beginners (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Options Trading Plan–Perfect For Beginners (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Options Trading Plan–Perfect For Beginners (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Options Trading Plan–Perfect For Beginners (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Options Trading Plan–Perfect For Beginners (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Options Trading Plan–Perfect For Beginners (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Options Trading Plan–Perfect For Beginners (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Options Trading Plan–Perfect For Beginners (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:UTHR

United Therapeutics (UTHR) Stock Forecast, Price & News

$222.75
-0.93 (-0.42%)
(As of 09/22/2023 ET)
Compare
Today's Range
$221.82
$225.00
50-Day Range
$217.48
$248.24
52-Week Range
$202.31
$283.09
Volume
163,675 shs
Average Volume
232,435 shs
Market Capitalization
$10.45 billion
P/E Ratio
12.60
Dividend Yield
N/A
Price Target
$296.44

United Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
33.1% Upside
$296.44 Price Target
Short Interest
Healthy
2.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.00
Upright™ Environmental Score
News Sentiment
0.95mentions of United Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$6.07 M Sold Last Quarter
Proj. Earnings Growth
9.34%
From $18.95 to $20.72 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.14 out of 5 stars

Medical Sector

15th out of 965 stocks

Pharmaceutical Preparations Industry

5th out of 456 stocks


UTHR stock logo

About United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

UTHR Price History

UTHR Stock News Headlines

New gold-backed currency could kill the Dollar
Rumors are circulating of a new currency that will be backed by gold. A huge story, if true. And while it’s impossible to know how it will pan out, there’s one important move you should make right now, before this happens. It’s the best way to protect your wealth today. Because if you’re not careful, YOU could be the one who pays the price
New gold-backed currency could kill the Dollar
Rumors are circulating of a new currency that will be backed by gold. A huge story, if true. And while it’s impossible to know how it will pan out, there’s one important move you should make right now, before this happens. It’s the best way to protect your wealth today. Because if you’re not careful, YOU could be the one who pays the price
Goldman Sachs Remains a Sell on United Therapeutics (UTHR)
See More Headlines
Receive UTHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

UTHR Company Calendar

Last Earnings
8/02/2023
Today
9/24/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:UTHR
CUSIP
91307C10
Employees
985
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$296.44
High Stock Price Forecast
$375.00
Low Stock Price Forecast
$230.00
Forecasted Upside/Downside
+33.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$727.30 million
Pretax Margin
52.98%

Debt

Sales & Book Value

Annual Sales
$1.94 billion
Cash Flow
$17.08 per share
Book Value
$105.24 per share

Miscellaneous

Free Float
41,066,000
Market Cap
$10.45 billion
Optionable
Optionable
Beta
0.62

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Martine A. Rothblatt J.D.Dr. Martine A. Rothblatt J.D. (Age 68)
    M.B.A., Ph.D., Founder, Chairman & CEO
    Comp: $5.32M
  • Mr. Michael I. Benkowitz (Age 51)
    Pres & COO
    Comp: $2.83M
  • Mr. James C. Edgemond (Age 55)
    CFO & Treasurer
    Comp: $2.01M
  • Mr. Paul A. Mahon J.D.Mr. Paul A. Mahon J.D. (Age 59)
    Exec. VP, Gen. Counsel & Corp. Sec.
    Comp: $2.31M
  • Mr. Dewey Steadman C.F.A.
    Head of Investor Relations
  • Ms. Holly Hobson
    Associate VP of HR
  • Kevin T. Gray
    Sr. VP of Strategic Operations & Logistics
  • Mr. Patrick Poisson (Age 55)
    Exec. VP of Technical Operations
  • Dr. Leigh Peterson
    Sr. VP of Product Devel.
  • Mr. Gil Golden
    Sr. VP & Chief Medical Officer













UTHR Stock - Frequently Asked Questions

Should I buy or sell United Therapeutics stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last twelve months. There are currently 1 sell rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" UTHR shares.
View UTHR analyst ratings
or view top-rated stocks.

What is United Therapeutics' stock price forecast for 2023?

9 brokers have issued 1 year target prices for United Therapeutics' shares. Their UTHR share price forecasts range from $230.00 to $375.00. On average, they predict the company's stock price to reach $296.44 in the next year. This suggests a possible upside of 33.1% from the stock's current price.
View analysts price targets for UTHR
or view top-rated stocks among Wall Street analysts.

How have UTHR shares performed in 2023?

United Therapeutics' stock was trading at $278.09 at the start of the year. Since then, UTHR stock has decreased by 19.9% and is now trading at $222.75.
View the best growth stocks for 2023 here
.

Are investors shorting United Therapeutics?

United Therapeutics saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 1,090,000 shares, a decline of 42.3% from the August 15th total of 1,890,000 shares. Based on an average daily volume of 332,900 shares, the short-interest ratio is currently 3.3 days.
View United Therapeutics' Short Interest
.

When is United Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our UTHR earnings forecast
.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) released its quarterly earnings results on Wednesday, August, 2nd. The biotechnology company reported $5.24 earnings per share for the quarter, beating the consensus estimate of $4.57 by $0.67. The biotechnology company had revenue of $596.50 million for the quarter, compared to the consensus estimate of $524.18 million. United Therapeutics had a net margin of 41.29% and a trailing twelve-month return on equity of 17.52%. United Therapeutics's quarterly revenue was up 27.8% on a year-over-year basis. During the same period in the prior year, the business posted $2.41 earnings per share.

What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO?

64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees.

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.86%), Renaissance Technologies LLC (4.66%), State Street Corp (4.00%), Geode Capital Management LLC (1.72%), Bank of New York Mellon Corp (1.27%) and Dimensional Fund Advisors LP (1.14%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon and Raymond Dwek.
View institutional ownership trends
.

How do I buy shares of United Therapeutics?

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $222.75.

How much money does United Therapeutics make?

United Therapeutics (NASDAQ:UTHR) has a market capitalization of $10.45 billion and generates $1.94 billion in revenue each year. The biotechnology company earns $727.30 million in net income (profit) each year or $17.68 on an earnings per share basis.

How many employees does United Therapeutics have?

The company employs 985 workers across the globe.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The official website for the company is www.unither.com. The biotechnology company can be reached via phone at (301) 608-9292, via email at ir@unither.com, or via fax at 301-608-9291.

This page (NASDAQ:UTHR) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -